Abstract
Objectives To compare the clinical characteristics between the rapid cohort and the normal cohort of erythrocyte sedimentation rate (ESR) in COVID-19 infections, analyze the variables with significant differences, and explore the influencing factors of rapid ESR.
Methods Selected a total of 80 patients with ESR detection during hospitalization were measured in 146 patients who received medical observation in concentrated isolation hospital in Guizhou province in China, collected and compared demographic information, epidemiological data, clinical symptoms, laboratory test data and CT image data during the observation between rapid cohort and normal group of ESR.
Results By comparison, the proportion of male in the rapid cohort was higher than female. The average age was more than 35 years old, with a large age gap. The proportion of severe and critical patients was more than 26.53% (13/49). However, in the normal cohort the proportion of female was more than male, and the average age was about 8 years lower than the rapid cohort, and the age gap was smaller. The proportion of severe and critical patients was 12.90%, which was less than half of the rapid group. In the two groups, the proportion of clustered cases accounted for more than 50%, and the average number of patients in one family was more than 3. The most common clinical symptoms were cough, sputum, fever, sore throat and weakness of limbs. There were significant differences in ALT, γ-GT and C-reactive protein between the rapid and normal cohort (P<0.05), but no statistically significant in other indicators. Hemoglobin and C-reactive protein have a significant effect on erythrocyte sedimentation rate.
Conclusions In this study, we found that ESR is related to Hemoglobin and C-reactive protein. (Funded by Science and Technology Department of Guizhou Province; Chinese ClinicalTrials.gov number, ChiCTR2000033346. opens in new tab.)
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This study was registered in Chinese Clinical Trial Registry Center. (CCTR number: ChiCTR 2000033346, registered 28 May 2020. URL: http://www.chictr.org.cn/edit.aspx?pid=53859&htm=4)
Clinical Protocols
http://www.chictr.org.cn/edit.aspx?pid=53859&htm=4.
Funding Statement
This study was supported by Science and Technology Support Plan of Guizhou Province in 2019 (Qian Ke He Support [2019] 2834) and Science and Technology Plan of Guizhou Province in 2020 (Qian Ke He Fundamental [2020] 1Z061).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of Affiliated Hospital of Zunyi Medical University.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(Email: Can Jin: jincancan0618{at}163.com; Linlin Wu: kelsi500{at}sina.com; Hong Mei: 2448789732{at}qq.com; Miao Chen: chenmiao64{at}163.com)
(Youshu Yuan, Email: 2271048509{at}qq.com)
(Email: Shucheng Zhang: zhangchunlei761{at}163.com; Zhixu He: hzx{at}gmc.edu.cn)
(Email: Zhixia Jiang: jzxhl{at}126.com)
Data Availability
I had full access to all of the data in this study and I take complete responsibility for the integrity of the data and the accuracy of the data analysis.